Background
Methods
Design and sampling
Procedure
Data analysis
Ethical approval
Results
Baseline characteristics of the study population (Table 1)
All | HIV-uninfected | HIV-unknown | HIV-infected | |||||
---|---|---|---|---|---|---|---|---|
N (822) | (%) | N (440) | (53.50%) | N (204) | (24.80%) | N (178) | (21.70%) | |
Gender, n (%) | ||||||||
Male, | 378 | (46.0) | 234 | (53.2) | 70 | (38.9)* | 66 | (37.1)* |
Female | 444 | (54.0) | 206 | (46.8) | 110 | (61.1) | 112 | (62.9) |
Age | ||||||||
Median (IQR) | 52 | (37–67) | 50 | (39–62) | 71 | (60–78)* | 35 | (30–44)* |
Primary diagnosis | ||||||||
Infection (other than TB) | 145 | (19) | 55 | (13.3) | 26 | (16.0) | 54 | ((31.6)* |
Tuberculosis | 92 | (12) | 32 | (7.7) | 4 | (2.5)* | 56 | (32.7)* |
Acute coronary syndrome | 93 | (12) | 50 | (12.1) | 40 | (24.7)* | 2 | (1.2)* |
Stroke | 66 | (8) | 28 | (9.2) | 28 | (17.3)* | 6 | (3.5)* |
CCF | 60 | (8) | 38 | (6.8) | 8 | (4.9) | 6 | (3.5)* |
COPD | 38 | (5) | 28 | (6.8) | 8 | (4.9) | 2 | (1.2)* |
Cancer | 28 | (4) | 18 | (4.3) | 4 | (2.5) | 6 | (3.5) |
Barthell pre-admission function, n (%) | ||||||||
< 50 | 72 | (8.8) | 26 | (5.9) | 24 | (11.8)* | 14 | (7.9) |
Mortality | ||||||||
In-Patient | 42 | (5.1) | 18 | (4.1) | 12 | (6) | 12 | (6.7) |
3mo | 122 | (14.8) | 54 | (12.3) | 38 | (19) | 22 | (12.4) |
12mo | 164 | (20.0) | 76 | (17.3) | 38 | (19) | 38 | (21.3) |
Performance of the identification tool
No IDed (%) | Sensitivity | Specificity | PPV | NPV | LR + | LR- | |
---|---|---|---|---|---|---|---|
Overall | |||||||
SQ + criteria | 366 (45%) | 0.77 (0.71–0.83) | 0.64 (0.60–0.68) | 0.35 (0.30–0.40) | 0.92 (0.89–0.94) | 2.13 (1.87–2.43) | 0.36 (0.27–0.48) |
Criteria only | 218 (27%) | 0.74 (0.68–0.81) | 0.85 (|0.83–0.88)* | 0.56 (0.49–0.63)* | 0.93 (0.91–0.95) | 5.10 (4.15–6.26)* | 0.30 (0.23–0.39) |
HIV-uninfected | |||||||
SQ + criteria | 166 (38%) | 0.68 (0.58–0.79) | 0.69 (0.64–0.73) | 0.31 (0.24–0.38) | 0.31 (0.24–0.38) | 2.18 (1.76–2.71) | 0.46 (0.33–0.64) |
Criteria only | 104 (24%) | 0.71 (0.61–0.81) | 0.86 (0.86–0.83)* | 0.52 (0.42–0.62)* | 0.52 (0.42–0.62)* | 5.17 (3.85–6.95)* | 0.34 (0.24–0.48) |
HIV-infected | |||||||
SQ + criteria | 76 (43%) | 0.74 (0.60–0.88) | 0.66 (0.58–0.74) | 0.37 (0.26–0.48) | 0.90()0.84–0.96) | 2.15 (1.60–2.89) | 0.40 (0.23–0.69) |
Criteria only | 34 (19%) | 0.58 (0.42–0.74) | 0.91 (0.87–0.96)** | 0.65 (0.49–0.81)* | 0.89 (0.84–0.94) | 6.75 (3.69–12.37)* | 0.46 (0.32–0.67) |
Characteristics and outcomes of patients “identified” vs “non-identified”
“Non-identified” | “Identified” | |
---|---|---|
N (604) | N (218) | |
Gender | ||
Male | 280 (46%) | 98 (45%) |
Female | 324 (54%) | 120 (55%) |
Age | ||
Median (IQR) | 49 (35–61) | 61 (48–75) |
lowest - 30 | 100 | 14 |
31–40 | 80 | 14 |
41–50 | 104 | 20 |
51–60 | 112 | 24 |
61–70 | 56 | 44 |
71–80 | 60 | 48 |
81 and older | 22 | 28 |
Primary diagnosis | ||
Infection (other than Tb) | 123 (20.4%) | 22 (10.1%) |
Tuberculosis | 78 (12.9%) | 14 (6.4%) |
Acute coronary syndrome | 85 (14.1%) | 8 (3.7%) |
Stroke | 26 (4.3%) | 40 (18.3%) |
CCF | 22 (3.6%) | 38 (17.4%) |
COPD | 18 (3.0%) | 20 (9.2%) |
Cancer | 10 (1.7%) | 18 (8.3%) |
HIV status | ||
Uninfected | 336 (55.6%) | 104 (47.7%) |
Infected | 144 (23.8%) | 34 (15.6%) |
Unknown | 114 (18.9%) | 66 (30.3%) |
Refused | 10 (1.7%) | 14 (6.4%) |
Barthell pre-admission function | ||
< 50 | 52 (8.6%) | 20 (9.2%) |
Mortality | ||
In-Patient | 8 (1.3%) | 34 (16%) |
3mo | 18 (3.0%) | 104 (48%) |
12mo | 42 (7.0%) | 122 (56%) |